MYC Hyperactivates Wnt Signaling in /-Mutated Colorectal Cancer Cells Through MiR-92a-Dependent Repression of
Overview
Authors
Affiliations
Activation of Wnt signaling is among the earliest events in colon cancer development. It is achieved either via activating mutations in the gene encoding β-catenin, the key transcription factor in the Wnt pathway, or most commonly by inactivating mutations affecting APC, a major β-catenin binding partner and negative regulator. However, our analysis of recent Pan Cancer Atlas data revealed that mutations significantly co-occur with those affecting Wnt receptor complex components (e.g., Frizzled and LRP6), underscoring the importance of additional regulatory events even in the presence of common / mutations. In our effort to identify non-mutational hyperactivating events, we determined that KRAS-transformed murine colonocytes overexpressing direct β-catenin target show significant upregulation of the Wnt signaling pathway and reduced expression of Dickkopf 3 (DKK3), a reported ligand for Wnt co-receptors. We demonstrate that MYC suppresses transcription through one of miR-17-92 cluster miRNAs, miR-92a. We further examined the role of DKK3 by overexpression and knockdown and discovered that DKK3 suppresses Wnt signaling in -null murine colonic organoids and human colon cancer cells despite the presence of downstream activating mutations in the Wnt pathway. Conversely, MYC overexpression in the same cell lines resulted in hyperactive Wnt signaling, acquisition of epithelial-to-mesenchymal transition markers, and enhanced migration/invasion and metastasis in a syngeneic orthotopic mouse colon cancer model. IMPLICATIONS: Our results suggest that the MYC→miR-92a-|DKK3 axis hyperactivates Wnt signaling, forming a feed-forward oncogenic loop.
A novel de novo truncating variant in a Hungarian patient with CTNNB1 neurodevelopmental disorder.
Nagy N, Pal M, Nagy D, Bokor B, Zimmermann A, Gellen B BMC Pediatr. 2024; 24(1):47.
PMID: 38225558 PMC: 10789033. DOI: 10.1186/s12887-023-04509-w.
Park M, Zaw T, Yoder S, Gomez M, Genilo-Delgado M, Basinski T G3 (Bethesda). 2022; 13(2).
PMID: 36454217 PMC: 9911050. DOI: 10.1093/g3journal/jkac314.
Li H, Xie C, Lu Y, Chang K, Guan F, Li X Biomolecules. 2022; 12(10).
PMID: 36291656 PMC: 9599242. DOI: 10.3390/biom12101448.
Drug-Resistant Stem Cells: Novel Approach for Colon Cancer Therapy.
Telang N Int J Mol Sci. 2022; 23(5).
PMID: 35269660 PMC: 8910557. DOI: 10.3390/ijms23052519.